Latest Breaking News On - Personalis inc - Page 9 : comparemela.com

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

17.01.2024 - Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors granted non-qualified stock options to purchase an aggregate of 29,000 shares of its .

United statesPersonalis incPersonalis stock

Personalis Announces Medicare Coverage for NeXT Dx(R) Comprehensive Genomic Tumor Profiling Assay

NeXT Dx helps clinicians make informed, personalized cancer treatment selections and match patients with clinical trials Access to NeXT Dx expands to the 66 million Medicare and Medicare Advantage.

United statesChris hallExchange commissionPersonalis incMedicare advantageLocal coverage determinationGeneration sequencingChief executive officer

Personalis Announces Medicare Coverage for NeXT Dx(R) Comprehensive Genomic Tumor Profiling Assay

Personalis, Inc. , a leader in advanced genomics for precision oncology, today announced it has received a final Medicare coverage determination for its NeXT Dx ultra-comprehensive tumor genomic profiling assay, providing access for the nation's 66.

United statesChris hallPersonalis incExchange commissionProduct serviceAnnounces medicare coverageComprehensive genomic tumor profilingMedicare advantageLocal coverage determinationGeneration sequencingChief executive officer

Personalis (PSNL) Reports Preliminary Fourth Quarter and Full Year 2023 Revenue and Cash Balance

Personalis (PSNL) Reports Preliminary Fourth Quarter and Full Year 2023 Revenue and Cash Balance
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Chris hallAdministration million veteran programPersonalis incFourth quarter revenueAdministration million veteranFull year

Personalis Reports Preliminary Fourth Quarter and Full Year 2023 Revenue and Cash Balance

Personalis, Inc. , a leader in advanced genomics for precision oncology, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2023. Preliminary.

United statesChris hallExchange commissionAdministration million veteran programPersonalis incFourth quarter revenueAdministration million veteranFull yearPrivate securities litigation reform actFinancial conditionPersonali annual reportQuarterly report